Gastroretentive Drug Delivery Systems Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others) By Region & Competition, 2021-2031F

The Global Gastroretentive Drug Delivery Systems Outsourcing Market is anticipated to grow from USD 1.41 Million in 2025 to USD 1.97 Million by 2031, at a 5.73% CAGR. Gastroretentive Drug Delivery Systems (GRDDS) are specialized oral solid dosage forms engineered to prolong gastric residence time, thereby enhancing the bioavailability of therapeutics with narrow absorption windows or localized stomach activity. This global outsourcing market is primarily driven by the pharmaceutical industry's strategic focus on lifecycle management through the reformulation of off-patent drugs and the imperative to improve patient adherence via reduced dosing frequencies. These fundamental drivers necessitate the utilization of contract development and manufacturing organizations (CDMOs) that possess the niche technical expertise required to engineer these complex retention mechanisms. Despite facing significant challenges due to high inter-subject variability of gastric physiology, which complicates in vivo-in vitro correlation and regulatory validation, the reliance on specialized external partners is reinforced, with 49% of surveyed pharmaceutical professionals in 2024 predicting a very positive outlook for contract services growth.

Market Driver

The increasing complexity of gastroretentive formulations, demanding specialized expertise, serves as a primary catalyst for the expansion of the outsourcing sector. Developing sophisticated delivery systems, such as expandable or floating dosage forms, requires niche capabilities in polymer science and process engineering often lacking internally within many pharmaceutical companies. Consequently, manufacturers increasingly utilize CDMOs to navigate these technical intricacies and access proprietary technologies without heavy internal capital investment. This trend is amplified by the high volume of new drug approvals, with 55 new molecular entities approved by the US FDA in the preceding year, necessitating advanced formulation technologies to address solubility and stability challenges. Simultaneously, the escalating prevalence of chronic diseases accelerates the demand for bioavailability enhancement in oral therapeutics, requiring consistent plasma drug concentrations, a key benefit of GRDDS for drugs with narrow absorption windows. This includes the projected 2,001,140 new cancer cases in the United States in 2024, driving the need for effective oral oncolytics. To meet such global health needs, the industry is witnessing significant consolidation, exemplified by Novo Holdings' $16.5 billion acquisition of Catalent in 2024, underscoring the strategic value placed on specialized production assets.

Market Challenge

The high inter-subject variability of gastric physiology stands out as a formidable challenge that directly hampers the growth of the Global Gastroretentive Drug Delivery Systems (GRDDS) Outsourcing Market. This biological inconsistency, wherein gastric emptying rates differ significantly among patients due to factors such as diet, stress, and disease state, complicates the establishment of a reliable In Vitro In Vivo Correlation (IVIVC). Consequently, contract development and manufacturing organizations (CDMOs) struggle to design predictive formulations, leading to extended development timelines and higher attrition rates during clinical validation. This technical uncertainty forces pharmaceutical sponsors to hesitate before committing capital to these complex programs, as the risk of regulatory rejection due to inconsistent bioavailability remains prohibitively high. The financial impact of overcoming these physiological hurdles creates a significant barrier to market expansion, necessitating larger, more expensive clinical trials to prove efficacy across diverse patient populations. The pharmaceutical industry's approximately €55 billion investment in R&D in Europe in 2024 underscores the immense capital resources required to navigate the intensifying regulatory and technical complexities associated with advanced drug delivery systems, with this escalating cost burden disproportionately affecting niche segments like GRDDS and restricting the volume of active outsourcing contracts.

Market Trends

The adoption of 3D printing is fundamentally transforming the development of gastroretentive formulations by enabling the fabrication of complex geometries that traditional compression techniques cannot achieve. This additive manufacturing approach allows contract development and manufacturing organizations to engineer intricate internal structures, such as expandable matrices or rigid floating systems, which are essential for prolonging gastric residence time and controlling drug release kinetics with high precision. The commercial viability of this technology for difficult-to-formulate therapies is increasingly recognized by major industry players seeking to overcome bioavailability barriers, exemplified by Triastek's strategic collaboration worth up to $1.2 billion with BioNTech in July 2024 to develop 3D-printed oral therapeutics. Simultaneously, there is a pronounced strategic migration of manufacturing and development activities to emerging Asian hubs, particularly India, to leverage a maturing high-tech supply chain. Western pharmaceutical sponsors are moving beyond simple cost-arbitrage models, now partnering with these regional vendors to access specialized capabilities in novel drug delivery systems and large-scale capacity for fixed-dose combinations. This expansion is evidenced by the rapid growth of industrial infrastructure dedicated to supporting global outsourcing mandates, with the CPHI & PMEC India event in November 2024 hosting over 2,000 exhibitors, a record number that underscores the region's deepening capacity to handle the technical and volume requirements of the global pharmaceutical market.

Key Market Players

• Catalent, Inc
• Lonza Group
• Evonik Industries AG
• Colorcon Inc.
• Quotient Sciences Holding Limited
• AptarGroup, Inc.
• Aenova Holding GmbH
• Evotec SE
• Vectura Group Ltd
• Ashland Inc.

Report Scope

In this report, the Global Gastroretentive Drug Delivery Systems Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastroretentive Drug Delivery Systems Outsourcing Market, By Dosage Form

• Tablets
• Liquid
• Microspheres
• Capsule
• Others

Gastroretentive Drug Delivery Systems Outsourcing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastroretentive Drug Delivery Systems Outsourcing Market.

Available Customizations:

Global Gastroretentive Drug Delivery Systems Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).